Navigation Links
Moody's Raises Rating for Gerresheimer
Date:3/17/2008

DUSSELDORF, Germany, March 17 /PRNewswire-FirstCall/ -- The rating agency Moody's has raised the rating for the Gerresheimer Group from Ba3 to Ba2 with "Outlook stable".

As a result, the Group's financial standing in the market and its refinancing possibilities are substantially enhanced. Moody's justifies this step by reference to the considerably strengthened business profile as a result of successful acquisitions and in view of the Group's increased profitability and cash flow strength. In the detailed justification, Moody's emphasises the company's leading market position and its stable customer relationships in the pharmaceutical and cosmetics industries.

"We are very pleased about the better rating by Moody's. It confirms our successful business development and solid financial structure. On this basis we will again grow profitably in 2008," says Dr. Axel Herberg, CEO of Gerresheimer AG.

About Gerresheimer

Gerresheimer employs more than 10,800 people in 41 locations in Europe, America and Asia. In the financial year 2007, worldwide sales totalled EUR957.7m. The product portfolio ranges from pharmaceutical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterized by high technical and regulatory barriers.

Contact Press

Burkhard Lingenberg

Director Corporate PR & Marketing

Telephone: +49-211-6181-250

Telefax: +49-211-6181-241

e-mail: b.lingenberg@gerresheimer.com e-mail

Contact Investor Relations

Anke Linnartz

Director Corporate Investor Relations

Telephone: +49-211-6181-314

Telefax: +49-211-6181-121

e-mail: a.linnartz@gerresheimer.com


'/>"/>
SOURCE Gerresheimer AG
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pearl Therapeutics Raises $15.5 Million in Private Financing
2. Enobia Pharma Raises $40.1 Million Series B Financing
3. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
4. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
5. VisEn Medical Raises $7 Million in Series B Financing
6. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
9. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
10. Anesiva Raises $45 Million in Common Stock Offering
11. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017 UCHealth ( Aurora, Colorado ... pulmonary nodule patient management. In addition to optimizing care ... on the lung, UCHealth looks to improve provider workflow ... Stephanie Brown, RN , Thoracic Nurse ... with an Excel spreadsheet, which was extremely arduous and ...
(Date:2/16/2017)... , Feb. 16, 2017  Windtree Therapeutics, Inc. ... focusing on developing aerosolized KL4 surfactant therapies for ... preclinical influenza study showed that aerosolized KL4 surfactant ... a well-established preclinical animal model. The Company believes ... body of evidence that supports the role of ...
(Date:2/15/2017)... (PRWEB) , ... February 15, 2017 , ... ... Posard, as President and Chief Commercial Officer with GenePeeks. Matt is a ... , GenePeeks is a computational genomics company focused on identifying inherited disease risk ...
(Date:2/15/2017)... WASHINGTON, Feb. 15, 2017  Vanda Pharmaceuticals Inc. ... results for the fourth quarter and full year ... an exceptional year for Vanda as we continued ... and secured long-term exclusivity for Fanapt," said Mihael ... addition, our emerging pipeline with important 2017 milestones ...
Breaking Biology Technology:
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2016. Revenue ... to $6.9 million in the same quarter last year. Operating ... compared to $2.6 million in the fourth quarter of 2015. ... million, or $0.02 per diluted share, which compares to $1.8 ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet ... in musculoskeletal healthcare, will present at the LEERINK Partners ... York Palace Hotel on Wednesday, February 15, 2017 at ... webcast of the presentation can be accessed at ... following the conference via Zimmer Biomet,s Investor Relations website ...
Breaking Biology News(10 mins):